Colon and Rectal Cancer Drugs; Help Maximize the Effect of Adjuvant Therapies for Colon and Rectal Cancer

 Colon and rectal cancer drugs are used to treat colon and rectal cancer. Colorectal cancer, also known as colon cancer, is a type of cancer that begins in the large intestine (colon). Treatment for colorectal cancer usually involves surgery to remove cancer. Other treatments, such as radiation therapy and chemotherapy, might also be recommended. Rectal cancer is a disease in which cancer cells develop in the rectum. Rectal cancer is curable, especially when detected early through screening methods like a colonoscopy.

Treatments include surgery, chemotherapy, and radiation therapy. Surgery is the removal of the tumor and some surrounding healthy tissue during an operation. It is called surgical resection. This is the most common treatment for colon and rectal cancer. Colon cancer can also be treated using drugs, which can be given by mouth or directly into the blood Some drugs commonly used for colorectal cancer include 5-Fluorouracil (5-FU), Irinotecan (Camptosar), Capecitabine (Xeloda), Oxaliplatin (Eloxatin), and Trifluridine and tipiracil (Lonsurf).

Due to a lack of development in the neoadjuvant/adjuvant pipeline medicines for the treatment of high-risk colorectal cancer, the colon and rectal cancer market treatments grew more slowly.



While, drugs approved for rectal cancer include 5Fluorouracil Injection, -FU (Fluorouracil Injection), Erbitux (Cetuximab), Eloxatin (Oxaliplatin), Cyramza (Ramucirumab), Cetuximab, Capecitabine, Bevacizumab, Avastin (Bevacizumab), Camptosar (Irinotecan Hydrochloride), and Trifluridine and Tipiracil Hydrochloride, among others. There are more colon cancer and rectal cancer drugs that are not listed here. There is an increasing demand for colon and rectal cancer drugs due to the increasing prevalence of colon and rectal cancer worldwide.

Colon and rectal cancer is the third most common cancer in both females and males, and colon cancer is the third most common cancer diagnosed in both men and women in the United States. For example, according to the American Cancer Society, in 2022, an estimated 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will be diagnosed in the U.S. Moreover, in May 2020, the U.S. Food and Drug Administration (FDA) approved encorafenib (Braftovi) for the treatment of some patients with colorectal cancer.

Post a Comment

Previous Post Next Post